obesity drug

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is

26 December 2025

Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly and Company (NYSE: LLY) ended Friday, December 19, 2025, with a solid gain, then barely budged in after-hours trading—an important clue about how investors are digesting the latest wave of obesity-drug headlines heading into next week. One key

20 December 2025

Earnings Reports · Financial News · Investing · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05

11 December 2025

Company Earnings · Health Industry · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. (NYSE: PFE) finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market

10 December 2025

NYSE:PFE · Obesity Treatment · Pfizer · Pharmaceutical Industry · Pre-Market Analysis · Stock Market

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

As of December 9, 2025, iBio, Inc. (NASDAQ: IBIO) has turned into one of the louder tickers in the obesity‑drug corner of biotech. After closing Monday, December 8 at $1.67, up 39% on the day, IBIO is trading higher again

9 December 2025

Biotechnology · Investment News · Market Analysis · Obesity · Stocks

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about

9 December 2025

Biotechnology · Investment News · NASDAQ:WVE · NYSE:NVO · Obesity Treatment · Pharmaceutical Industry · Stock Market

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a

9 December 2025

Biotech · Investing · NASDAQ:WVE · Obesity Treatments · Pharmaceutical News · Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 WVE stock more than doubles on massive volume Wave Life Sciences Ltd. (NASDAQ: WVE) staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007.

8 December 2025

Biotechnology · Investment · NASDAQ:WVE · Obesity · Stocks · Wall Street

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

Viking Therapeutics (NASDAQ: VKTX) has quietly become one of the most closely watched small-cap names in the weight-loss drug trade. As of the last trading session on Friday, December 5, 2025, VKTX closed at $38.55, giving the company a market

7 December 2025

Biotech · Financial Forecasts · Investment · NASDAQ:VKTX · Obesity Treatment · Stock Market

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the

15 November 2025

Financial Results · Healthcare · Market Trends · NYSE:LLY · Pharmaceuticals · Stock Analysis

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of

4 November 2025

Earnings Reports · Investment Analysis · NYSE:NVO · NYSE:PFE · Pfizer News · Pharmaceutical Industry · Stock Market

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus

4 November 2025

Drug Development · Earnings Reports · Market Analysis · NYSE:PFE · Obesity Treatments · Pharmaceuticals